In human asthma, a significant role of the transcription factor GATA‐3 was determined for a Th2‐dominated phenotype.79 Therefore, GATA‐3 has already been evaluated as a target protein in asthma therapy for humans.79 An increase from GATA‐3, as in the beclomethasone group after 8 weeks, would therefore be considered unfavourable for the progression of the disease. This evidence concerns the gene GATA3 and asthma.